Foghorn Therapeutics, Inc. FHTX 深 沪
等待开盘 05-29 09:30:00 美东时间
4.27
0.000
0.00%
华盛通- 最 高4.3972
- 今 开4.24
- 成交量 10.47万股
- 最 低 4.12
- 昨 收 4.27
- 总市值 2.51亿
- 52周最高 6.95
- 市盈率 静 --
- 换手率 0.18%
- 52周最低 3.27
- 委 比 -80.65%
- 总股本 5871.39万
- 历史最高 28.265
- 量 比 0.60
- 振 幅 6.49%
- 历史最低 2.70
- 每 手 1
- 风险率 0.61%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Foghorn Therapeutics Q1 EPS $(0.29), Inline, Sales $3.267M Miss $7.438M Estimate
Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.29) per share which met the analyst consensus estimate. This is a 3.33 percent increase over losses of $(0.30) per share from the same period last year.
05-07 21:11
Foghorn Therapeutics Presents New Preclinical Data For Selective SMARCA2 Inhibitor FHD-909 And For Selective CBP, EP300 And ARID1B Degrader Programs
- Complete and durable regression and anti-tumor immune memory following treatment with FHD-909 (LY4050784) in combination with an anti-PD-1 antibody in preclinical syngeneic mouse models- Selective CBP
04-22 04:15
Foghorn Therapeutics To Share New Cancer Drug Data At Major Research Conference
Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that it will
04-09 19:10
美股大行评级 | 潜在涨幅101%！甲骨文获花旗升目标价至320美元，维持"买入"评级
今日重点评级关注：Freedom Capital Markets：维持LifeMD"买入"评级，目标价从8美元升至10美元；Chardan Capital：维持Opus Genetics"买入"评级，目标价从9美元升至11美元
03-13 09:59
美股大行评级 | 潜在涨幅467.73%！Corbus制药控股获Oppenheimer升目标价至57美元，维持"跑赢大市"评级
今日重点评级关注：Oppenheimer：维持Corbus制药控股"跑赢大市"评级，目标价从53美元升至57美元；Canaccord Genuity：维持WAVE Life Sciences"买入"评级，目标价从43美元升至52美元
03-11 12:40
HC Wainwright & Co. Reiterates Buy on Foghorn Therapeutics, Maintains $13 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and maintains $13 price target.
03-10 19:27
Reported Friday, Foghorn Therapeutics Secures $50M Equity Financing, Advances Oncology Pipeline, And Extends $208.9M Cash Runway Into First Half Of 2028
Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund in a transaction that will close January 13th, 2026Phase 1 dose-escalation
01-12 16:37
美股大行评级 | 潜在涨幅101%！12家机构集体上调美光目标价；Insmed、RPM、Vital Farms等遭多家大行下调评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从22美元升至22.5美元；HC Wainwright & Co.：维持Climb Bio"买入"评级，目标价从9美元升至11美元
2025-12-19 10:15
BTIG Initiates Coverage On Foghorn Therapeutics with Buy Rating, Announces Price Target of $11
BTIG analyst Jeet Mukherjee initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Buy rating and announces Price Target of $11.
2025-12-18 20:19
